CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...